Case Reports
Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol
Affiliations
- PMID: 7752364
Item in Clipboard
Case Reports
Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol
J Urol.
1995 Jun.
Abstract
The phenomenon of regression of adenocarcinoma of the prostate after the withdrawal of antiandrogens is well documented. However, to our knowledge we report the first case of durable complete remission of hormone refractory prostate cancer after cessation of diethylstilbestrol. The drug was discontinued because the patient had disease progression while on diethylstilbestrol and withdrawal resulted in durable remission. In more than 3 years of followup since discontinuing diethylstilbestrol there has been no evidence of clinical or biochemical recurrence.
Similar articles
-
Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.Am J Clin Oncol. 2008 Apr;31(2):188-94. doi: 10.1097/COC.0b013e3181595af6. Am J Clin Oncol. 2008. PMID: 18391605
-
Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.Urol Oncol. 2005 Jan-Feb;23(1):1-7. doi: 10.1016/j.urolonc.2004.06.003. Urol Oncol. 2005. PMID: 15885575 Clinical Trial.
-
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.Cancer. 2007 Sep 1;110(5):996-1002. doi: 10.1002/cncr.22917. Cancer. 2007. PMID: 17639587 Clinical Trial.
-
Management of hormone refractory prostate cancer: current standards and future prospects.J Urol. 1998 Oct;160(4):1220-9. J Urol. 1998. PMID: 9751323 Review.
-
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.Urology. 2005 Sep;66(3):658. doi: 10.1016/j.urology.2005.03.028. Urology. 2005. PMID: 16140106 Review.
Cited by
-
Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report.J Med Case Rep. 2014 Apr 9;8:122. doi: 10.1186/1752-1947-8-122. J Med Case Rep. 2014. PMID: 24717107 Free PMC article.
-
Secondary hormonal manipulations in prostate cancer.Curr Oncol Rep. 2005 May;7(3):228-33. doi: 10.1007/s11912-005-0078-x. Curr Oncol Rep. 2005. PMID: 15847715 Review.
-
Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.Drug Saf. 2000 Nov;23(5):381-90. doi: 10.2165/00002018-200023050-00003. Drug Saf. 2000. PMID: 11085345 Review.
-
Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.Mol Oncol. 2014 Dec;8(8):1575-87. doi: 10.1016/j.molonc.2014.06.009. Epub 2014 Jun 24. Mol Oncol. 2014. PMID: 25091737 Free PMC article.
-
Secondary hormonal manipulation of prostate cancer.Curr Urol Rep. 2001 Jun;2(3):224-30. doi: 10.1007/s11934-001-0083-z. Curr Urol Rep. 2001. PMID: 12084269 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical